Gapping up
In reaction to earnings/guidance:
- LEVI +13.4%, PERI +12%, IART +5.7% (upside Q3 rev guidance), RPM +2.5%, LMNX +1.8%, MASI +1.3% (guides Q3 and FY20 product revs above consensus)
Other news:
- TLC +90.9% (receives approval in Australian and Taiwan to initiate Phase I clinical trial of TLC19 Inhalable Liposomal Hydroxychloroquine for COVID-19)
- PSTI +6.3% (receives approval in Israel to expand its Phase II COVID-19 European Clinical Trial)
- ETON +3% (submits NDA for topiramate oral solution to the FDA)
- NAVI +2.8% (new CFO)
- SRNE +2.7% (announces continuous sales growth in ZTlido and expects to complete enrollment on its SP-102 (SEMDEXA) Phase 3 pivotal trial program in 2020)
- IGT +2.6% (provides update on LOTEX concession in Brazil)
- SIRI +2.5% (nearing deal with Howard Stern, according to Bloomberg)
- BA +1.7% (FAA releases new pilot-training requirements for 737 MAX)
- LINC +1.7% (stock offering)
- SRAC +1.6% (Stable Road Acquisition Corp and Momentus to merge to create the first publicly traded space infrastructure company at the forefront of the new space economy)
Analyst comments:
- JBLU +6.2% (upgraded to Overweight from Underweight at JP Morgan)
- COTY +4.6% (upgraded to Buy from Hold at Jefferies)
- SAVE +4.1% (upgraded to Neutral from Underweight at JP Morgan)
- PTCT +4% (upgraded to Overweight from Neutral at JP Morgan)
- UAL +4% (upgraded to Overweight from Neutral at JP Morgan)
- AEO +3.1% (upgraded to Overweight from Equal Weight at Barclays)
- GPS +3.1% (upgraded to Overweight from Underweight at Barclays)
- WDAY +2.8% (upgraded to Buy from Hold at Jefferies)
- BUD +2.7% (upgraded to Buy from Hold at Jefferies)
- KTB +2.5% (upgraded to Overweight from Equal Weight at Barclays)
- FL +2.2% (upgraded to Overweight from Equal Weight at Barclays)
- VSH +2.1% (upgraded to Buy from Hold at Stifel)
- NFLX +1.6% (target raised to a Street-high $650 at Pivotal Research Group)
- MMM +1.3% (upgraded to Hold from Underperform at Gordon Haskett)
- DEO +1.3% (upgraded to Buy from Underperform at Jefferies)
- PM +1.2% (upgraded to Buy from Neutral at Citigroup)